Maxim Remains Positive on Kite Pharma (KITE) Following CAR/TCR Pipeline, KTE-C19 Launch Update; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Kite Pharma (KITE) Announces Details on CAR/TCR Pipeline, KTE-C19 Launch Outlook
October 19, 2016 8:42 AM EDTKite Pharma, Inc. (Nasdaq: KITE) presented updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates and KTE-C19 launch readiness at its Investor Day in New York on October 18, 2016.
At Kite, our goal is to cure cancer. With KTE-C19, we may have the opportunity to transform the treatment of aggressive non-Hodgkin lymphoma (NHL), said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. While we prepare to manufacture and commercialize KTE-C19 upon approval, we believe this is just the beginning. The breadth of... More
Kite Pharma (KITE): Notes From R&D Day - Jefferies
October 19, 2016 7:29 AM EDTJefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after the company's annual R&D investor where the company shared its vision to bring KTE-C19 forward to the market, discussed mfr, reimbursement, and detailed launch strategy. KITE continues to invest in multiple trials for KTE-C19 to drive potentially broader use longer term.... More
